First-in-class ERK1/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: Results of a phase I dose-escalation and expansion study

Ryan J. Sullivan*, Jeffrey R. Infante, Filip Janku, Deborah Jean Lee Wong, Jeffrey A. Sosman, Vicki Keedy, Manish R. Patel, Geoffrey I. Shapiro, James W. Mier, Anthony W. Tolcher, Andrea Wang-Gillam, Mario Sznol, Keith Flaherty, Elizabeth Buchbinder, Richard D. Carvajal, Anna M. Varghese, Mario E. Lacouture, Antoni Ribas, Sapna P. Patel, Gary A. DeCrescenzoCaroline M. Emery, Anna L. Groover, Saurabh Saha, Mary Varterasian, Dean J. Welsch, David M. Hyman, Bob T. Li

*Corresponding author for this work

Research output: Contribution to journalArticle

99 Scopus citations

Abstract

Ulixertinib (BVD-523) is an ERK1/2 kinase inhibitor with potent preclinical activity in BRAF- and RAS-mutant cell lines. In this multicenter phase I trial (NCT01781429), 135 patients were enrolled to an accelerated 3 + 3 dose-escalation cohort and six distinct dose-expansion cohorts. Dose escalation included 27 patients, dosed from 10 to 900 mg twice daily and established the recommended phase II dose (RP2D) of 600 mg twice daily. Ulixertinib exposure was dose proportional to the RP2D, which provided near-complete inhibition of ERK activity in whole blood. In the 108-patient expansion cohort, 32% of patients required dose reduction. The most common treatmentrelated adverse events were diarrhea (48%), fatigue (42%), nausea (41%), and dermatitis acneiform (31%). Partial responses were seen in 3 of 18 (17%) patients dosed at or above maximum tolerated dose and in 11 of 81 (14%) evaluable patients in dose expansion. Responses occurred in patients with NRAS-, BRAF V600-, and non-V600 BRAF -mutant solid tumors. Significance: Here, we describe the fi rst-in-human dose-escalation study of an ERK1/2 inhibitor for the treatment of patients with advanced solid tumors. Ulixertinib has an acceptable safety profi le with favorable pharmacokinetics and has shown early evidence of clinical activity in NRAS - and BRAF V600-and non-V600 mutant solid-tumor malignancies.

Original languageEnglish (US)
Pages (from-to)184-195
Number of pages12
JournalCancer discovery
Volume8
Issue number2
DOIs
StatePublished - Feb 2018

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'First-in-class ERK1/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: Results of a phase I dose-escalation and expansion study'. Together they form a unique fingerprint.

  • Cite this

    Sullivan, R. J., Infante, J. R., Janku, F., Lee Wong, D. J., Sosman, J. A., Keedy, V., Patel, M. R., Shapiro, G. I., Mier, J. W., Tolcher, A. W., Wang-Gillam, A., Sznol, M., Flaherty, K., Buchbinder, E., Carvajal, R. D., Varghese, A. M., Lacouture, M. E., Ribas, A., Patel, S. P., ... Li, B. T. (2018). First-in-class ERK1/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: Results of a phase I dose-escalation and expansion study. Cancer discovery, 8(2), 184-195. https://doi.org/10.1158/2159-8290.CD-17-1119